The Company's Product, hyaluronic acid
Flexotron Forte (1%) has obtained medical device
license.
Date of events
2022/06/09
To which item it meets
paragraph 51
Statement
1.Date of occurrence of the event:2022/06/09
2.Company name:SciVision Biotech Inc.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:Flexotron Forte(1%), hyaluronic acid developed and
produced by the company, has passed and obtained the medical device
license (P3H 2022/17365).
6.Countermeasures:make this announcement
7.Any other matters that need to be specified:This product contains
hyaluronic acid, which can increase joint lubrication and reduce joint
friction. For the majority of patients with degenerative knee arthritis,
it can inhibit the degeneration of cartilage, promote its metabolism,
relieve pain and discomfort, improve daily activities and increase range
of activities of joints. Russia has a population of 147 million, of which
about 13% have osteoarthritis. The company has obtained the Russian
national medical device license, which can increase the sales performance
in the Russian market and contribute to the company's revenue.
Attachments
Original Link
Original Document
Permalink
Disclaimer
SciVision Biotech Inc. published this content on 09 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 June 2022 10:41:05 UTC.
SciVision Biotech Inc is principally engaged in the manufacturing and distribution of hyaluronic acid medical supplies. The Company primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The Company is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The Company operates its business in the Americas, Europe, Asia, Middle East and Africa.
SCIVISION BIOTECH INC. 
